Patents by Inventor Stuart A. Sievers

Stuart A. Sievers has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20250145707
    Abstract: Provided is a chimeric antigen receptor (CAR) or a T cell receptor (TCR) comprising one or more of the antigen binding motifs disclosed herein. Aspects of the disclosure relate to a polynucleotide encoding a chimeric antigen receptor (CAR) or a T cell receptor (TCR) comprising one or more of the antigen binding motifs. Provided are antibodies and antigen binding systems that comprise a binding motif that binds CD20 and optionally a binding motif that binds CD19, and methods of producing and using the same. Antibodies and antigen binding systems of the present disclosure comprise CARs that comprise an anti-CD20 binding motif and an anti-CD19 binding motif. Provided are compositions, such as antibodies and CARs that are or comprise an anti-CD20/anti-CD19 antigen binding system of the present disclosure, and cell therapies comprising the same, are useful, e.g., in the treatment of cancer.
    Type: Application
    Filed: December 31, 2024
    Publication date: May 8, 2025
    Inventors: Arianne Perez, Stuart A. Sievers, Ruben Alvarez Rodriguez, Jonathan Belk, Jed Wiltzius
  • Publication number: 20240343820
    Abstract: The present disclosure describes antigen binding molecules, including antibodies, that specifically bind to the anti-CD20 scFv-14 or Gibbon ape leukemia virus gp70 protein, as well as molecules comprising the described sequences and cells presenting such molecules. The antigen binding molecules may be used in research, diagnostic, clinical, and other applications.
    Type: Application
    Filed: March 6, 2024
    Publication date: October 17, 2024
    Inventors: Michael E. Coon, Christa Cortesio, Stuart A. Sievers
  • Publication number: 20240150750
    Abstract: Isolated antigen binding molecules that specifically binds to a molecule comprising an amino acid sequence selected from the group consisting of GGGS (SEQ ID NO: 1), GGGGS (SEQ ID NO: 46) and related sequences are provided. The antigen binding molecules may be used in the methods provided herein.
    Type: Application
    Filed: October 25, 2023
    Publication date: May 9, 2024
    Inventors: Stuart A. Sievers, Jed J.W. Wiltzius
  • Publication number: 20240115611
    Abstract: Provided is a chimeric antigen receptor (CAR) or a T cell receptor (TCR) comprising one or more of the antigen binding motifs disclosed herein. Aspects of the disclosure relate to a polynucleotide encoding a chimeric antigen receptor (CAR) or a T cell receptor (TCR) comprising one or more of the antigen binding motifs. Provided are antibodies and antigen binding systems that comprise a binding motif that binds CD20 and optionally a binding motif that binds CD19, and methods of producing and using the same. Antibodies and antigen binding systems of the present disclosure comprise CARs that comprise an anti-CD20 binding motif and an anti-CD19 binding motif. Provided are compositions, such as antibodies and CARs that are or comprise an anti-CD20/anti-CD19 antigen binding system of the present disclosure, and cell therapies comprising the same, are useful, e.g., in the treatment of cancer.
    Type: Application
    Filed: September 20, 2023
    Publication date: April 11, 2024
    Inventors: Arianne Perez, Stuart A. Sievers, Ruben Alvarez Rodriguez, Jonathan Belk, Jed Wiltzius
  • Patent number: 11834654
    Abstract: Isolated antigen binding molecules that specifically binds to a molecule comprising an amino acid sequence selected from the group consisting of GGGS (SEQ ID NO: 1), GGGGS (SEQ ID NO: 46) and related sequences are provided. The antigen binding molecules may be used in the methods provided herein.
    Type: Grant
    Filed: November 10, 2020
    Date of Patent: December 5, 2023
    Assignee: Kite Pharma, Inc.
    Inventors: Jed J. W. Wiltzius, Stuart A. Sievers
  • Patent number: 11793834
    Abstract: Provided is a chimeric antigen receptor (CAR) or a T cell receptor (TCR) comprising one or more of the antigen binding motifs disclosed herein. Aspects of the disclosure relate to a polynucleotide encoding a chimeric antigen receptor (CAR) or a T cell receptor (TCR) comprising one or more of the antigen binding motifs. Provided are antibodies and antigen binding systems that comprise a binding motif that binds CD20 and optionally a binding motif that binds CD19, and methods of producing and using the same. Antibodies and antigen binding systems of the present disclosure comprise CARs that comprise an anti-CD20 binding motif and an anti-CD19 binding motif. Provided are compositions, such as antibodies and CARs that are or comprise an anti-CD20/anti-CD19 antigen binding system of the present disclosure, and cell therapies comprising the same, are useful, e.g., in the treatment of cancer.
    Type: Grant
    Filed: December 11, 2019
    Date of Patent: October 24, 2023
    Assignee: Kite Pharma, Inc.
    Inventors: Arianne Perez, Stuart A. Sievers, Ruben Alvarez Rodriguez, Jonathan Belk, Jed Wiltzius
  • Publication number: 20230287054
    Abstract: The invention provides novel peptides (e.g., linkers) and polypeptide compositions comprising the linkers (e.g., fusion proteins) and methods of using the polypeptide compositions. Peptides (e.g., linkers) are useful as tags and for engineering fusion proteins (e.g., antigen binding molecules, scFv). Polypeptide linkers described herein facilitate flexibility of linked peptides allowing for proper folding, conformation and reduced immunogenicity.
    Type: Application
    Filed: December 20, 2022
    Publication date: September 14, 2023
    Inventors: Stuart A. Sievers, Jed J.W. Wiltzius
  • Publication number: 20230039418
    Abstract: The disclosure provides a chimeric antigen receptor (CAR) comprising a modified hinge, transmembrane and/or intracellular domain disclosed herein. Some aspects of the disclosure relate to a polynucleotide encoding a chimeric antigen receptor (CAR) comprising the costimulatory domain disclosed herein. Other aspects of the disclosure relate to cells comprising the CAR and use in a T cell therapy.
    Type: Application
    Filed: June 23, 2022
    Publication date: February 9, 2023
    Inventors: Stuart A. Sievers, Jed J.W. Wiltzius
  • Patent number: 11572388
    Abstract: The invention provides novel peptides (e.g., linkers) and polypeptide compositions comprising the linkers (e.g., fusion proteins) and methods of using the polypeptide compositions. Peptides (e.g., linkers) are useful as tags and for engineering fusion proteins (e.g., antigen binding molecules, scFv). Polypeptide linkers described herein facilitate flexibility of linked peptides allowing for proper folding, conformation and reduced immunogenicity.
    Type: Grant
    Filed: May 19, 2020
    Date of Patent: February 7, 2023
    Assignee: Kite Pharma, Inc.
    Inventors: Jed J. W. Wiltzius, Stuart A. Sievers
  • Publication number: 20220289829
    Abstract: This disclosure provides novel broadly neutralizing anti-HIV antibodies and antigen-binding fragments thereof. The disclosed anti-HIV antibodies exhibited improved biophysical properties, e.g, reduced polyreactivity, prolonged half-life, while retaining broad and potent neutralization activity. The anti-HIV bNAb variants as disclosed constitute a novel therapeutic strategy for treating and/or preventing HIV infection.
    Type: Application
    Filed: July 8, 2020
    Publication date: September 15, 2022
    Applicants: California Institute of Technology, The Rockefeller University
    Inventors: Stuart A. Sievers, Jennifer Keeffe, Michel C. Nussenzweig, Pamela J. Bjorkman
  • Patent number: 11390655
    Abstract: The disclosure provides a chimeric antigen receptor (CAR) comprising a modified hinge, transmembrane and/or intracellular domain disclosed herein. Some aspects of the disclosure relate to a polynucleotide encoding a chimeric antigen receptor (CAR) comprising the costimulatory domain disclosed herein. Other aspects of the disclosure relate to cells comprising the CAR and use in a T cell therapy.
    Type: Grant
    Filed: November 15, 2018
    Date of Patent: July 19, 2022
    Assignee: Kite Pharma, Inc.
    Inventors: Stuart A. Sievers, Jed J. W. Wiltzius
  • Publication number: 20210130808
    Abstract: Isolated antigen binding molecules that specifically binds to a molecule comprising an amino acid sequence selected from the group consisting of GGGS (SEQ ID NO: 1), GGGGS (SEQ ID NO: 46) and related sequences are provided. The antigen binding molecules may be used in the methods provided herein.
    Type: Application
    Filed: November 10, 2020
    Publication date: May 6, 2021
    Inventors: Jed J.W. WILTZIUS, Stuart A. SIEVERS
  • Publication number: 20210061910
    Abstract: The invention provides a humanized anti-CD19 antibody or antigen binding fragment thereof comprising a light chain variable (VL) region and a heavy chain variable (VH) region in which the humanized VL and VL regions are derived from the mouse anti-CD19 clone FMC63 antibody; the humanized VL and/or humanized VH region comprise one or more amino acid substitutions in the framework region. The humanized anti-CD19 antibody or antigen binding fragment may be part of a single chain variable fragment (scFv), a chimeric antigen receptor (CAR) or a T cell receptor (TCR). Other aspects of the invention relate to cells comprising the CAR or the TCR and their use in a T cell therapy.
    Type: Application
    Filed: November 10, 2020
    Publication date: March 4, 2021
    Inventors: Jed J.W. WILTZIUS, Stuart A. SIEVERS
  • Publication number: 20200399320
    Abstract: The invention provides novel peptides (e.g., linkers) and polypeptide compositions comprising the linkers (e.g., fusion proteins) and methods of using the polypeptide compositions. Peptides (e.g., linkers) are useful as tags and for engineering fusion proteins (e.g., antigen binding molecules, scFv). Polypeptide linkers described herein facilitate flexibility of linked peptides allowing for proper folding, conformation and reduced immunogenicity.
    Type: Application
    Filed: May 19, 2020
    Publication date: December 24, 2020
    Inventors: Jed J.W. WILTZIUS, Stuart A. SIEVERS
  • Patent number: 10844120
    Abstract: The invention provides a humanized anti-CD19 antibody or antigen binding fragment thereof comprising a light chain variable (VL) region and a heavy chain variable (VH) region in which the humanized VL and VL regions are derived from the mouse anti-CD19 clone FMC63 antibody; the humanized VL and/or humanized VH region comprise one or more amino acid substitutions in the framework region. The humanized anti-CD19 antibody or antigen binding fragment may be part of a single chain variable fragment (scFv), a chimeric antigen receptor (CAR) or a T cell receptor (TCR). Other aspects of the invention relate to cells comprising the CAR or the TCR and their use in a T cell therapy.
    Type: Grant
    Filed: April 24, 2018
    Date of Patent: November 24, 2020
    Assignee: Kite Pharma, Inc.
    Inventors: Jed J. W. Wiltzius, Stuart A. Sievers
  • Patent number: 10844371
    Abstract: Isolated antigen binding molecules that specifically binds to a molecule comprising an amino acid sequence selected from the group consisting of GGGS (SEQ ID NO: 1), GGGGS (SEQ ID NO: 46) and related sequences are provided. The antigen binding molecules may be used in the methods provided herein.
    Type: Grant
    Filed: September 21, 2018
    Date of Patent: November 24, 2020
    Assignee: Kite Pharma, Inc.
    Inventors: Jed J. W. Wiltzius, Stuart A. Sievers
  • Publication number: 20200246382
    Abstract: Provided is a chimeric antigen receptor (CAR) or a T cell receptor (TCR) comprising one or more of the antigen binding motifs disclosed herein. Aspects of the disclosure relate to a polynucleotide encoding a chimeric antigen receptor (CAR) or a T cell receptor (TCR) comprising one or more of the antigen binding motifs. Provided are antibodies and antigen binding systems that comprise a binding motif that binds CD20 and optionally a binding motif that binds CD19, and methods of producing and using the same. Antibodies and antigen binding systems of the present disclosure comprise CARs that comprise an anti-CD20 binding motif and an anti-CD19 binding motif. Provided are compositions, such as antibodies and CARs that are or comprise an anti-CD20/anti-CD19 antigen binding system of the present disclosure, and cell therapies comprising the same, are useful, e.g., in the treatment of cancer.
    Type: Application
    Filed: December 11, 2019
    Publication date: August 6, 2020
    Inventors: Arianne Perez, Stuart A. Sievers, Ruben Alvarez Rodriguez, Jonathan Belk
  • Publication number: 20190144515
    Abstract: The disclosure provides a chimeric antigen receptor (CAR) comprising a modified hinge, transmembrane and/or intracellular domain disclosed herein. Some aspects of the disclosure relate to a polynucleotide encoding a chimeric antigen receptor (CAR) comprising the costimulatory domain disclosed herein. Other aspects of the disclosure relate to cells comprising the CAR and use in a T cell therapy.
    Type: Application
    Filed: November 15, 2018
    Publication date: May 16, 2019
    Inventors: Stuart A. Sievers, Jed J. W. Wiltzius
  • Publication number: 20190093101
    Abstract: Isolated antigen binding molecules that specifically binds to a molecule comprising an amino acid sequence selected from the group consisting of GGGS (SEQ ID NO: 1), GGGGS (SEQ ID NO: 46) and related sequences are provided. The antigen binding molecules may be used in the methods provided herein.
    Type: Application
    Filed: September 21, 2018
    Publication date: March 28, 2019
    Inventors: Jed J.W. Wiltzius, Stuart A. Sievers
  • Publication number: 20190092818
    Abstract: The invention provides novel peptides (e.g., linkers) and polypeptide compositions comprising the linkers (e.g., fusion proteins) and methods of using the polypeptide compositions. Peptides (e.g., linkers) are useful as tags and for engineering fusion proteins (e.g., antigen binding molecules, scFv). Polypeptide linkers described herein facilitate flexibility of linked peptides allowing for proper folding, conformation and reduced immunogenicity.
    Type: Application
    Filed: September 21, 2018
    Publication date: March 28, 2019
    Inventors: Jed J.W. Wiltzius, Stuart A. Sievers